OraSure Technologies, Inc.
OSUROraSure Technologies, Inc. in brief
OraSure Technologies, Inc. is a listed company in the Medical Instruments industry, based in Bethlehem, Pennsylvania, USA. It was founded in 1987. Its market value was $262 M on 23 October 2026, which makes it the 15,291st largest listed company in the world and the 2,980th largest in the USA on this site. In the year to December 2025 it had sales of $115 M and a net loss of $69 M. It employs about 785 people and Manner Carrie Eglinton is its chief executive. Its largest product and service lines by sales in 2025 were Products and services (95%). By market, the largest shares of its 2025 sales came from USA (68%), Africa (21%) and Europe (6%). Its shares trade under the symbol OSUR (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About OraSure Technologies, Inc.
OraSure Technologies, Inc. is a Bethlehem, Pennsylvania–based company in the medical device industry. Their products include diagnostic testing kits. The company had recently developed OraQuick testing kit, the first over-the-counter home HIV test.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
OraSure Technologies, Inc. timeline
- 1987
- 🏁· approximateFounded
- 2000
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2018
- •Legal Entity Identifier issuedLEI 529900GNNJPNM4XHXQ77 registered.
- 2023
- 💰Record revenue of $405 millionFY2023, the highest of the 8 years on record.
- 💰Record net income of $54 millionFY2023, the highest profit of the 3 years on record.
Events of OraSure Technologies, Inc. from the company record, SEC EDGAR, the GLEIF LEI register and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,499 (Jan 2020) · #2,420 (Jan 2021) · #3,104 (Jan 2022) · #3,057 (Dec 2022) · #3,073 (Jul 2023) · #2,394 (Jan 2024) · #1,645 (Mar 2026) · #2,949 (Aug 2026) · #2,984 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 2.3×
- Price / book
- 0.8×
- Free cash flow yield
- -20.3%
- Net margin (TTM)
- -41.7%
- Operating margin
- -62.6%
- Return on equity
- -14.2%
- Liabilities / assets
- 15.5%
- Revenue growth
- -38.1%
- R&D / revenue
- 37.0%
- Revenue per employee
- $147 K
- Profit per employee
- $-88 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $115M | -38.1% | $-72M | $-69M | -59.8% |
| Dec 2024 | $186M | -54.2% | $-28M | $-20M | -10.5% |
| Dec 2023 | $405M | +4.6% | $33M | $54M | 13.2% |
| Dec 2022 | $387M | +65.8% | $-22M | $-17M | -4.4% |
| Dec 2021 | $234M | +36.1% | $-10M | $-23M | -9.8% |
| Dec 2020 | $172M | +11.1% | $-5M | $-15M | -8.7% |
| Dec 2019 | $155M | -14.9% | $19M | $17M | 10.8% |
| Dec 2018 | $182M | — | $28M | $20M | 11.2% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-49M | $4M | $-53M | $-0.94 | — |
| Dec 2024 | $27M | $4M | $24M | $-0.26 | — |
| Dec 2023 | $142M | $6M | $136M | $0.72 | — |
| Dec 2022 | $-47M | $7M | $-54M | $-0.24 | — |
| Dec 2021 | $-35M | $22M | $-57M | $-0.32 | — |
| Dec 2020 | $6M | $27M | $-21M | $0.22 | — |
| Dec 2019 | $10M | $9M | $0M | $0.27 | — |
| Dec 2018 | $39M | $6M | $33M | $0.33 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $31M (+14.1% on a year earlier), net income $-13M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-Q/AQuarterly report (amended) · period to Sep 2026
- Nov 9, 202610-QQuarterly report · period to Sep 2026
- Nov 9, 20268-KCurrent reportResults of operations
- Aug 7, 202610-QQuarterly report · period to Jun 2026
- Aug 5, 20268-KCurrent reportResults of operations
- Jun 11, 20268-KCurrent reportOther events
- Jun 3, 20268-KCurrent reportDirectors or officers changed · Bylaws amended · Shareholder vote
- May 8, 202610-QQuarterly report · period to Mar 2026
- May 6, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Apr 30, 2026DEF 14AProxy statement
- Apr 17, 20268-KCurrent reportMaterial agreement · Directors or officers changed · Regulation FD disclosure
- Mar 30, 20268-KCurrent reportRegulation FD disclosure
Official filings of OraSure Technologies, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $115 M
- Operating income
- $-72 M
- Net income
- $-69 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $403 M
- Total liabilities
- $62 M
- Total equity
- $341 M
As of December-2025
Top 100 institutional investors in OraSure Technologies, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 6,073,705 | -183,057 (-2.93%) | 8.80% | $24 M | Nov 13, 2026 |
| 2 | Neuberger Berman Group LLC | 4,089,876 | -595,556 (-12.71%) | 5.92% | $16 M | Nov 13, 2026 |
| 3 | Yorkville Advisors Global, LP | 3,929,970 | New | 5.69% | $15 M | Nov 12, 2026 |
| 4 | Altai Capital Management, L.P. | 3,613,836 | 0 (0.00%) | 5.23% | $14 M | Nov 16, 2026 |
| 5 | Private Management Group Inc | 3,180,007 | -617,675 (-16.26%) | 4.61% | $12 M | Nov 4, 2026 |
| 6 | Systematic Financial Management LP | 3,148,036 | +290,062 (+10.15%) | 4.56% | $12 M | Nov 16, 2026 |
| 7 | Vanguard Capital Management LLC | 2,900,213 | -118,694 (-3.93%) | 4.20% | $11 M | Nov 13, 2026 |
| 8 | Dimensional Fund Advisors LP | 2,255,527 | -85,374 (-3.65%) | 3.27% | $9 M | Nov 4, 2026 |
| 9 | Acadian Asset Management LLC | 2,022,119 | 0 (0.00%) | 2.93% | $8 M | Nov 9, 2026 |
| 10 | Renaissance Technologies LLC | 1,954,203 | -60,700 (-3.01%) | 2.83% | $8 M | Nov 12, 2026 |
| 11 | Gagnon Securities LLC | 1,826,604 | +234,457 (+14.73%) | 2.65% | $7 M | Nov 5, 2026 |
| 12 | State Street Corp | 1,655,581 | -31,028 (-1.84%) | 2.40% | $6 M | Nov 12, 2026 |
| 13 | First Eagle Investment Management, LLC | 1,637,964 | -487,536 (-22.94%) | 2.37% | $6 M | Nov 10, 2026 |
| 14 | Geode Capital Management, LLC | 1,606,059 | -201,830 (-11.16%) | 2.33% | $6 M | Nov 6, 2026 |
| 15 | Gagnon Advisors, LLC | 1,285,032 | +77,592 (+6.43%) | 1.86% | $5 M | Nov 6, 2026 |
| 16 | Peapod Lane Capital LLC | 928,592 | -65,283 (-6.57%) | 1.34% | $4 M | Oct 22, 2026 |
| 17 | Wells Fargo & Company/mn | 885,047 | -38,983 (-4.22%) | 1.28% | $3 M | Nov 16, 2026 |
| 18 | D. E. Shaw & Co., Inc. | 703,682 | -123,505 (-14.93%) | 1.02% | $3 M | Nov 16, 2026 |
| 19 | Jacobs Levy Equity Management, Inc | 688,715 | -156,220 (-18.49%) | 1.00% | $3 M | Nov 16, 2026 |
| 20 | Jpmorgan Chase & Co | 621,687 | +32,510 (+5.52%) | 0.90% | $2 M | Nov 12, 2026 |
| 21 | Vanguard Portfolio Management LLC | 612,575 | -11,089 (-1.78%) | 0.89% | $2 M | Nov 13, 2026 |
| 22 | Goldman Sachs Group Inc | 611,624 | +49,974 (+8.90%) | 0.89% | $2 M | Nov 16, 2026 |
| 23 | Bank Of America Corp /de/ | 589,932 | +532,555 (+928.17%) | 0.85% | $2 M | Nov 16, 2026 |
| 24 | Charles Schwab Investment Management Inc | 574,898 | -4,685 (-0.81%) | 0.83% | $2 M | Nov 16, 2026 |
| 25 | Orion Porfolio Solutions, LLC | 571,397 | +234,998 (+69.86%) | 0.83% | $2 M | Nov 12, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Cannell Capital LLC | 568,071 | -859,348 (-60.20%) | 0.82% | $2 M | Nov 16, 2026 |
| 27 | Northern Trust Corp | 551,920 | -35,488 (-6.04%) | 0.80% | $2 M | Nov 16, 2026 |
| 28 | Tudor Investment Corp Et Al | 498,847 | +98,018 (+24.45%) | 0.72% | $2 M | Nov 16, 2026 |
| 29 | Vanguard Fiduciary Trust Co | 430,160 | -27,907 (-6.09%) | 0.62% | $2 M | Nov 13, 2026 |
| 30 | UBS Group AG | 412,751 | +152,765 (+58.76%) | 0.60% | $2 M | Nov 10, 2026 |
| 31 | Morgan Stanley | 394,264 | +58,628 (+17.47%) | 0.57% | $2 M | Nov 13, 2026 |
| 32 | KLP Kapitalforvaltning As | 363,300 | 0 (0.00%) | 0.53% | $1 M | Nov 10, 2026 |
| 33 | Man Group plc | 269,139 | +118,285 (+78.41%) | 0.39% | $1 M | Nov 16, 2026 |
| 34 | AQR Capital Management LLC | 238,930 | -80,913 (-25.30%) | 0.35% | $1 M | Nov 16, 2026 |
| 35 | Price T Rowe Associates Inc /MD/ | 231,771 | +1,601 (+0.70%) | 0.34% | $1 M | Nov 16, 2026 |
| 36 | Pavaki Capital Management LLC | 219,033 | 0 (0.00%) | 0.32% | $1 M | Oct 26, 2026 |
| 37 | Strs Ohio | 216,300 | +59,400 (+37.86%) | 0.31% | $1 M | Oct 30, 2026 |
| 38 | SEI Investments Co | 203,876 | -634 (-0.31%) | 0.30% | $1 M | Nov 10, 2026 |
| 39 | BlueCrest Capital Management Ltd | 200,000 | New | 0.29% | $1 M | Nov 13, 2026 |
| 40 | Bank of New York Mellon Corp | 199,919 | -7,700 (-3.71%) | 0.29% | $1 M | Nov 5, 2026 |
| 41 | American Century Companies Inc | 179,487 | -10,236 (-5.40%) | 0.26% | $1 M | Nov 12, 2026 |
| 42 | Invesco Ltd. | 174,625 | +41,658 (+31.33%) | 0.25% | $1 M | Nov 12, 2026 |
| 43 | Point72 Asset Management, L.P. | 172,502 | New | 0.25% | $1 M | Nov 16, 2026 |
| 44 | Gsa Capital Partners LLP | 168,086 | New | 0.24% | $1 M | Nov 16, 2026 |
| 45 | Ameriprise Financial Inc | 167,920 | -8,132 (-4.62%) | 0.24% | $1 M | Nov 16, 2026 |
| 46 | HRT Financial LP | 150,491 | New | 0.22% | $1 M | Nov 13, 2026 |
| 47 | Jump Financial, LLC | 138,900 | New | 0.20% | $1 M | Nov 13, 2026 |
| 48 | Odyssean, LLC | 133,937 | 0 (0.00%) | 0.19% | $1 M | Nov 16, 2026 |
| 49 | Nuveen, LLC | 131,361 | +29 (+0.02%) | 0.19% | $1 M | Nov 10, 2026 |
| 50 | Barclays PLC | 124,396 | +17,457 (+16.32%) | 0.18% | $0 M | Nov 6, 2026 |
| 51 | Boothbay Fund Management, LLC | 124,028 | +89,254 (+256.67%) | 0.18% | $0 M | Nov 16, 2026 |
| 52 | HSBC Holdings PLC | 115,405 | -4,025 (-3.37%) | 0.17% | $0 M | Nov 16, 2026 |
| 53 | Alliancebernstein L.P. | 108,816 | 0 (0.00%) | 0.16% | $0 M | Nov 16, 2026 |
| 54 | Bridgeway Capital Management, LLC | 103,647 | -31,512 (-23.31%) | 0.15% | $0 M | Nov 16, 2026 |
| 55 | Fuller & Thaler Asset Management, Inc. | 99,749 | +1,350 (+1.37%) | 0.14% | $0 M | Nov 13, 2026 |
| 56 | Citadel Advisors LLC | 91,291 | -10,667 (-10.46%) | 0.13% | $0 M | Nov 16, 2026 |
| 57 | Qube Research & Technologies Ltd | 89,529 | New | 0.13% | $0 M | Nov 13, 2026 |
| 58 | Empowered Funds, LLC | 88,488 | New | 0.13% | $0 M | Nov 13, 2026 |
| 59 | Murphy Pohlad Asset Management LLC | 85,667 | -20,600 (-19.39%) | 0.12% | $0 M | Oct 22, 2026 |
| 60 | Rhumbline Advisers | 85,387 | -2,877 (-3.26%) | 0.12% | $0 M | Nov 10, 2026 |
| 61 | Deutsche Bank AG\ | 85,145 | -33,080 (-27.98%) | 0.12% | $0 M | Nov 6, 2026 |
| 62 | Russell Investments Group, Ltd. | 79,651 | +7,897 (+11.01%) | 0.12% | $0 M | Nov 6, 2026 |
| 63 | Two Sigma Investments, LP | 72,742 | +13,442 (+22.67%) | 0.11% | $0 M | Nov 16, 2026 |
| 64 | FMR LLC | 70,062 | +59,737 (+578.57%) | 0.10% | $0 M | Nov 10, 2026 |
| 65 | Occudo Quantitative Strategies LP | 68,248 | New | 0.10% | $0 M | Nov 16, 2026 |
| 66 | Engineers Gate Manager LP | 47,958 | New | 0.07% | $0 M | Nov 16, 2026 |
| 67 | NewEdge Advisors, LLC | 47,759 | -502 (-1.04%) | 0.07% | $0 M | Nov 13, 2026 |
| 68 | Quadrature Capital Ltd | 44,484 | +16,569 (+59.36%) | 0.06% | $0 M | Nov 13, 2026 |
| 69 | Arrowstreet Capital, Limited Partnership | 42,983 | -103,042 (-70.56%) | 0.06% | $0 M | Nov 13, 2026 |
| 70 | Millennium Management LLC | 42,415 | -145,908 (-77.48%) | 0.06% | $0 M | Nov 16, 2026 |
| 71 | Susquehanna International Group, LLP | 39,079 | -159,700 (-80.34%) | 0.06% | $0 M | Nov 16, 2026 |
| 72 | MetLife Investment Management, LLC | 37,593 | -983 (-2.55%) | 0.05% | $0 M | Nov 16, 2026 |
| 73 | Franklin Templeton Inc | 36,390 | New | 0.05% | $0 M | Nov 12, 2026 |
| 74 | Metis Global Partners, LLC | 34,430 | 0 (0.00%) | 0.05% | $0 M | Nov 13, 2026 |
| 75 | State Board Of Administration Of Florida Retirement System | 34,338 | 0 (0.00%) | 0.05% | $0 M | Nov 13, 2026 |
| 76 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 31,791 | +1,597 (+5.29%) | 0.05% | $0 M | Nov 16, 2026 |
| 77 | Centiva Capital, LP | 31,658 | New | 0.05% | $0 M | Nov 13, 2026 |
| 78 | Manatuck Hill Partners, LLC | 30,000 | 0 (0.00%) | 0.04% | $0 M | Nov 16, 2026 |
| 79 | Graham Capital Management, L.P. | 26,034 | -18,267 (-41.23%) | 0.04% | $0 M | Nov 16, 2026 |
| 80 | Vanguard Global Advisers, LLC | 25,884 | +309 (+1.21%) | 0.04% | $0 M | Nov 13, 2026 |
| 81 | Bfsg, LLC | 24,970 | -2,650 (-9.59%) | 0.04% | $0 M | Oct 30, 2026 |
| 82 | Significant Wealth Partners LLC | 20,401 | -31 (-0.15%) | 0.03% | $0 M | Nov 12, 2026 |
| 83 | OneDigital Investment Advisors LLC | 20,290 | -184 (-0.90%) | 0.03% | $0 M | Nov 10, 2026 |
| 84 | Manufacturers Life Insurance Company, The | 19,742 | -809 (-3.94%) | 0.03% | $0 M | Nov 13, 2026 |
| 85 | New York State Common Retirement Fund | 19,307 | 0 (0.00%) | 0.03% | $0 M | Nov 17, 2026 |
| 86 | LPL Financial LLC | 17,278 | -1,350 (-7.25%) | 0.03% | $0 M | Nov 6, 2026 |
| 87 | Vanguard Personalized Indexing Management, LLC | 16,775 | 0 (0.00%) | 0.02% | $0 M | Nov 16, 2026 |
| 88 | Public Employees Retirement Association Of Colorado | 16,476 | 0 (0.00%) | 0.02% | $0 M | Nov 12, 2026 |
| 89 | Quantinno Capital Management LP | 16,307 | -4,306 (-20.89%) | 0.02% | $0 M | Nov 13, 2026 |
| 90 | Coldstream Capital Management Inc | 15,475 | -2,504 (-13.93%) | 0.02% | $0 M | Nov 9, 2026 |
| 91 | Quadrant Private Wealth Management, LLC | 15,260 | -5,000 (-24.68%) | 0.02% | $0 M | Nov 4, 2026 |
| 92 | Voya Investment Management LLC | 15,123 | -1,075 (-6.64%) | 0.02% | $0 M | Nov 10, 2026 |
| 93 | PNC Financial Services Group, Inc. | 15,089 | +1,214 (+8.75%) | 0.02% | $0 M | Nov 6, 2026 |
| 94 | Shikiar Asset Management Inc | 15,000 | 0 (0.00%) | 0.02% | $0 M | Oct 20, 2026 |
| 95 | Moors & Cabot, Inc. | 14,755 | 0 (0.00%) | 0.02% | $0 M | Nov 6, 2026 |
| 96 | Police & Firemen's Retirement System of New Jersey | 13,744 | -9,938 (-41.96%) | 0.02% | $0 M | Nov 9, 2026 |
| 97 | BNP Paribas Financial Markets | 13,743 | +5,519 (+67.11%) | 0.02% | $0 M | Nov 12, 2026 |
| 98 | Marshall Wace, LLP | 13,200 | -11,000 (-45.45%) | 0.02% | $0 M | Nov 13, 2026 |
| 99 | State Of Wisconsin Investment Board | 12,978 | -34,719 (-72.79%) | 0.02% | $0 M | Nov 16, 2026 |
| 100 | Schonfeld Strategic Advisors LLC | 11,935 | -15,060 (-55.79%) | 0.02% | $0 M | Nov 16, 2026 |
Mutual funds holding OraSure Technologies, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 2.15 M | $10 M | 3.1% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 1.75 M | $8 M | 2.5% | <0.01% | −0.9% | Jun 30, 2026 |
| 🇺🇸 Neuberger Intrinsic Value FundNeuberger Berman Investment Advisers LLC | 1.10 M | $5 M | 1.6% | 0.32% | −0.1% | May 31, 2026 |
| 🇺🇸 First Eagle Small Cap Opportunity FundFirst Eagle Investment Management, LLC | 1.17 M | $5 M | 1.7% | 0.16% | new | Jul 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 804,240 | $4 M | 1.2% | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 716,191 | $3 M | 1.0% | <0.01% | +4.9% | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 601,153 | $3 M | 0.87% | 0.02% | +2.3% | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap Value PortfolioDimensional Fund Advisors LP | 589,210 | $2 M | 0.85% | 0.01% | −15% | Jul 31, 2026 |
| 🇺🇸 BlackRock Advantage Small Cap Core FundBlackRock Advisors, LLC | 446,639 | $2 M | 0.65% | 0.04% | −1.3% | May 29, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 397,761 | $2 M | 0.58% | <0.01% | −0.3% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 358,419 | $2 M | 0.52% | <0.01% | +2.4% | May 31, 2026 |
| 🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc. | 339,139 | $1 M | 0.49% | <0.01% | −4.7% | May 31, 2026 |
| 🇺🇸 JPMorgan Small Cap Value FundJ.P. Morgan Investment Management Inc. | 297,538 | $1 M | 0.43% | 0.10% | +83% | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 306,565 | $1 M | 0.44% | <0.01% | +6.7% | Jul 31, 2026 |
| 🇺🇸 Column Small Cap Select FundTrust for Professional Managers | 241,719 | $1 M | 0.35% | 0.05% | +0.3% | May 31, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 243,672 | $1 M | 0.35% | 0.01% | +6.2% | Jul 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 220,490 | $1 M | 0.32% | 0.06% | +26% | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 228,516 | $1 M | 0.33% | <0.01% | −7.7% | Jul 31, 2026 |
| 🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc. | 195,698 | $1 M | 0.28% | <0.01% | +3.6% | May 31, 2026 |
| 🇺🇸 Multi-Manager Small Cap Equity Strategies FundColumbia Funds Series Trust I | 176,052 | $1 M | 0.25% | 0.06% | −19% | May 31, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 185,265 | $1 M | 0.27% | <0.01% | +24% | Jul 31, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 154,509 | $1 M | 0.22% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 140,145 | $1 M | 0.20% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 133,206 | $1 M | 0.19% | 0.02% | −6.8% | May 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 124,041 | $1 M | 0.18% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors | 123,087 | $1 M | 0.18% | <0.01% | +2.5% | Jun 30, 2026 |
| 🇺🇸 NVIT Multi-Manager Small Company FundNATIONWIDE FUND ADVISORS | 116,069 | $1 M | 0.17% | 0.11% | −16% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P. | 113,825 | $0 M | 0.16% | 0.05% | +1.3% | May 31, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 105,000 | $0 M | 0.15% | 0.32% | no change | Jun 30, 2026 |
| 🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP | 115,021 | $0 M | 0.17% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 NVIT Small Cap Value FundNATIONWIDE FUND ADVISORS | 104,238 | $0 M | 0.15% | 0.21% | −12% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 107,296 | $0 M | 0.16% | <0.01% | +2.7% | May 31, 2026 |
| 🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP | 103,715 | $0 M | 0.15% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 91,514 | $0 M | 0.13% | 0.02% | +5.5% | Jun 30, 2026 |
| 🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC | 90,352 | $0 M | 0.13% | 0.05% | −4.9% | May 31, 2026 |
| 🇺🇸 Transamerica Small/Mid Cap ValueTransamerica Asset Management, Inc. | 93,700 | $0 M | 0.14% | 0.06% | +8.6% | Jul 31, 2026 |
| 🇺🇸 Small Cap Equity FundGuideStone Capital Management, LLC | 78,730 | $0 M | 0.11% | 0.03% | −44% | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 75,678 | $0 M | 0.11% | <0.01% | −7.6% | Jun 30, 2026 |
| 🇺🇸 JPMorgan Small Cap Value PortfolioBrighthouse Investment Advisers, LLC | 74,915 | $0 M | 0.11% | 0.10% | +72% | Jun 30, 2026 |
| 🇺🇸 Transamerica Small/Mid Cap Value VPTransamerica Asset Management, Inc. | 73,800 | $0 M | 0.11% | 0.06% | −0.3% | Jun 30, 2026 |
| 🇺🇸 JPMorgan Diversified Return U.S. Small Cap Equity ETFJ.P. Morgan Investment Management Inc. | 81,069 | $0 M | 0.12% | 0.06% | +3.7% | Jul 31, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 70,686 | $0 M | 0.10% | 0.02% | +0.4% | Jun 30, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 74,228 | $0 M | 0.11% | 0.01% | −29% | Jul 31, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 71,140 | $0 M | 0.10% | <0.01% | −28% | Jul 31, 2026 |
| 🇺🇸 Dimensional US Small Cap Value ETFDimensional Fund Advisors LP | 61,708 | $0 M | 0.09% | <0.01% | −11% | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 53,758 | $0 M | 0.08% | 0.02% | −3.1% | May 31, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 55,033 | $0 M | 0.08% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc. | 51,155 | $0 M | 0.07% | <0.01% | +0.9% | May 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 49,206 | $0 M | 0.07% | <0.01% | −7.2% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 45,433 | $0 M | 0.07% | <0.01% | +71% | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Equity ETFAmerican Century ETF Trust | 44,087 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 43,371 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Column Small Cap FundTrust for Professional Managers | 41,233 | $0 M | 0.06% | 0.03% | no change | May 31, 2026 |
| 🇺🇸 Transamerica Small Cap ValueTransamerica Asset Management, Inc. | 43,500 | $0 M | 0.06% | 0.16% | +26% | Jul 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 36,693 | $0 M | 0.05% | <0.01% | −20% | Jun 30, 2026 |
| 🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP | 39,492 | $0 M | 0.06% | <0.01% | +199% | Jul 31, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 35,020 | $0 M | 0.05% | <0.01% | −32% | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 37,455 | $0 M | 0.05% | <0.01% | +14% | Jul 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 33,395 | $0 M | 0.05% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 32,916 | $0 M | 0.05% | <0.01% | +12% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Extended Equity Market Index FundT. Rowe Price Associates, Inc. | 31,882 | $0 M | 0.05% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 35,000 | $0 M | 0.05% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 30,211 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Value FundThe Variable Annuity Life Insurance Company | 31,160 | $0 M | 0.05% | 0.05% | −11% | May 31, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 30,575 | $0 M | 0.04% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 31,322 | $0 M | 0.05% | <0.01% | +3.8% | Jul 31, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 25,821 | $0 M | 0.04% | <0.01% | −2.1% | Jul 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 23,000 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 21,650 | $0 M | 0.03% | <0.01% | −5.3% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 20,750 | $0 M | 0.03% | <0.01% | −0.8% | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 20,519 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 16,567 | $0 M | 0.02% | <0.01% | −24% | Jun 30, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 16,939 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 16,106 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 15,628 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 15,247 | $0 M | 0.02% | 0.01% | +8.1% | Jun 30, 2026 |
| 🇺🇸 Omni Small-Cap Value FundBridgeway Capital Management, LLC | 15,000 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 14,652 | $0 M | 0.02% | 0.03% | +17% | Jun 30, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 14,307 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP | 13,900 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc. | 11,732 | $0 M | 0.02% | 0.01% | −4.6% | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 10,936 | $0 M | 0.02% | 0.01% | +16% | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Equity Market ETFDimensional Fund Advisors LP | 11,179 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 11,090 | $0 M | 0.02% | 0.01% | +2.4% | Jul 31, 2026 |
| 🇺🇸 U.S. Social Core Equity 2 PortfolioDimensional Fund Advisors LP | 11,009 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 9,840 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vericimetry U.S. Small Cap Value FundVericimetry Funds | 9,693 | $0 M | 0.01% | 0.02% | +87% | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 9,491 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 10,337 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 8,690 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 8,556 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity FundAmerican Century ETF Trust | 8,199 | $0 M | 0.01% | 0.03% | no change | May 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 7,452 | $0 M | 0.01% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP | 8,145 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 7,789 | $0 M | 0.01% | <0.01% | −26% | Jul 31, 2026 |
| 🇺🇸 AST Small-Cap Equity PortfolioAST Investment Services, Inc. | 6,831 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 7,490 | $0 M | 0.01% | <0.01% | +0.4% | Jul 31, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 6,570 | $0 M | <0.01% | <0.01% | +40% | Jun 30, 2026 |
| 🇺🇸 Dimensional US Vector Equity ETFDimensional Fund Advisors LP | 7,100 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP | 7,000 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at OraSure Technologies, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Steven Kyle BoydDirector | Grant or award | +4,797 | $3.880 | $19 K | 168,031 | Form 4 |
| filed | John P. KennyDirector | Shares withheld for tax | -5,116 | $3.430 | $18 K | 204,598 | Form 4 |
| filed | Steven Kyle BoydDirector | Grant or award | +3,666 | $4.430 | $16 K | 163,234 | Form 4 |
| filed | Robert W. McMahonDirector | Grant or award | +46,106 | — | — | 123,137 | Form 4 |
| filed | Nancy J. GaglianoDirector | Grant or award | +46,106 | — | — | 185,055 | Form 4 |
| filed | John D. BertrandDirector | Grant or award | +46,106 | — | — | 79,767 | Form 4 |
| filed | Steven Kyle BoydDirector | Grant or award | +46,106 | — | — | 159,568 | Form 4 |
| filed | Lelio MarmoraDirector | Grant or award | +46,106 | — | — | 148,460 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: OraSure Technologies, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q3 2026 | Q3 2026 | $0M |
| Q2 2026 | Q2 2026 | $2M |
| Q1 2026 | Q1 2026 | $5M |
| Q4 2025 | Q4 2025 | $5M |
| Q3 2025 | Q3 2025 | $5M |
| Q2 2025 | Q2 2025 | $5M |
| Q1 2025 | Q1 2025 | $0M |
| Q4 2024 | Q4 2024 | $0M |
| Q3 2024 | Q3 2024 | $0M |
| Q1 2024 | Q1 2024 | $1.5M |
| Q3 2023 | Q3 2023 | $0.2M |
| Q2 2023 | Q2 2023 | $0.5M |
| Q1 2023 | Q1 2023 | $1.2M |
| Q4 2022 | Q4 2022 | $0.2M |
| Q3 2022 | Q3 2022 | $0.1M |
| Q2 2022 | Q2 2022 | $0.9M |
Trading halts
- 2025-02-26 14:31 UTC, code LUDP, resumed 14:36 UTC
Fails to deliver
- : 1,106 shares at $3.80
- : 14,635 shares at $3.39
- : 4,133 shares at $3.58
- : 88 shares at $3.53
- : 745 shares at $3.60
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
OraSure Technologies, Inc. scorecard#
Passes 6 of the 23 checks that could be worked out: strongest in financial health (2 of 3), weakest in growth (0 of 6). Fiscal year 2025; market cap of Oct 23, 2026.
Valuation2 of 6
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.8×Price to book 0.8× against Medical Instruments's median of 3.9×.
- ✓Price to sales below its peers' median2.3×Price to sales 2.3× against Medical Instruments's median of 3.0×.
- ✗Free cash flow yield above 5%-20.3%Free cash flow is -20.3% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- ✗The price assumes slower growth than the last three years'-5.9%The price assumes -5.9% a year for ten years; revenue grew -33.3% a year over the last three.
Growth0 of 6
- ✗Revenue grew in the newest year-38.1%Revenue down 38.1% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-33.3%-33.3% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-33.3%-33.3% a year against Medical Instruments's median of 5.0% (37 companies).
- ✗Earnings per share grew in the newest year-0.94 vs -0.26Diluted EPS -0.94 in fiscal 2025 against -0.26 the year before (report's currency).
- ✗Net income higher than five years earlier-$69 M-$69 M in fiscal 2025 against -$15 M in 2020.
- ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
Profitability0 of 5
- ✗Profitable in the newest year-$69 MNet income -$69 M in fiscal 2025.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-62.6%-62.6% against Medical Instruments's median of 7.2% (46 companies).
- ✗Return on equity above 15%-18.3%-18.3% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier-62.6%-62.6% in fiscal 2025 against -5.7% in 2022.
Financial health2 of 3
- ✓Short-term assets cover short-term liabilities6.6×Current ratio 6.58 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years2 of 3Positive in 2 of the three years to fiscal 2025.
- ✓Altman Z-score outside the distress zone2.28Z-score 2.28 (grey zone) for fiscal 2025.
Shareholder returns2 of 3
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year-1.3%Diluted shares down 1.3% in fiscal 2025.
- ✓Dividends and buybacks above 3% of the market value5.7%Dividends and buybacks were 5.7% of the market value.
- ✗Free cash flow covers dividends and buybacks-$53 MFree cash flow -$53 M against $15 M paid out in fiscal 2025.
Worked out from the statements as filed (sec), the medians of Medical Instruments, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from OraSure Technologies, Inc.'s statements, beside the median of Medical Instruments.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -62.6% | 7.2% | |
| Net margin | -59.8% | 3.8% | |
| Return on equity | -18.3% | 3.5% | |
| Revenue growth, 3 years a year | -33.3% | 5.0% | |
| Revenue growth | -38.1% | 8.9% | |
| Free cash flow margin | -46.3% | 6.3% |
2of 8on the Piotroski tests of financial strength
- Revenue fell 38.1% against the year before.
- Net loss of $69 million.
- Free cash flow was negative: -$53 million.
OraSure Technologies, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 115−38.1%100% | 186−54.2%100% | 405+4.6%100% | 387+65.8%100% | 234+36.1%100% | 172+11.1%100% | 155−14.9%100% | 182+8.8%100% | 167+30.3%100% | 128—100% | |
| Cost of revenue | 67−37.2%58.1% | 106−54.5%57.3% | 234−2.2%57.7% | 239r240+106%61.7% | 116+66.2%49.7% | 70+16.4%40.7% | 60−11.9%38.8% | 68+0.0%37.5% | 68+69.5%40.8% | 40—31.3% | |
| Gross profit | 48−39.3%41.9% | 79−53.7%42.7% | 172+15.6%42.3% | 148r148+26.2%38.3% | 118+15.4%50.3% | 102+7.7%59.3% | 95−16.7%61.2% | 114+14.8%62.5% | 99+12.4%59.2% | 88—68.7% | |
| Research and development | 43+63.3%37.0% | 26−22.8%14.0% | 34−6.9%8.3% | 36+6.0%9.4% | 34+10.1%14.6% | 31+58.1%18.1% | 20+20.8%12.7% | 16+21.6%8.9% | 13+37.0%8.0% | 9.8—7.6% | |
| Selling and marketing | 26−15.7%22.7% | 31−14.7%16.7% | 36−26.2%9.0% | 49+10.0%12.7% | 45+29.9%19.2% | 34+8.1%20.1% | 32+4.1%20.6% | 31+7.3%16.8% | 29−3.8%17.1% | 30—23.1% | |
| General and administrative | 48+3.2%41.5% | 46−20.6%24.9% | 58−14.7%14.4% | 68+35.5%17.6% | 50+18.0%21.5% | 43+20.9%24.8% | 35−7.9%22.8% | 38+30.7%21.1% | 29+3.4%17.6% | 28—22.1% | |
| Operating expenses | 120+11.6%104% | 108−22.5%57.9% | 139−18.5%34.3% | 171+33.5%44.0% | 128+19.4%54.7% | 107+40.9%62.3% | 76−10.8%49.1% | 85+45.1%46.9% | 59−13.3%35.1% | 68—52.9% | |
| Operating income | −72—−62.6% | −28−186%−15.2% | 33—8.1% | −22r−23—−5.7% | −10—−4.3% | −5.2−128%−3.0% | 19−34.5%12.0% | 28−29.3%15.6% | 40+98.6%24.1% | 20—15.8% | |
| Interest and finance income | 8.1−29.6%7.0% | 11+95.6%6.2% | 5.9+274%1.4% | 1.6—0.4% | — | — | — | — | — | — | |
| Share of profit of associates | −2.3—−2.0% | −1.7—−0.9% | 0—0.0% | 0—0.0% | — | — | — | — | — | — | |
| Other non-operating income (expense) | 0.2—0.2% | −0.4−102%−0.2% | 18r24+417%4.4% | 3.5r6.5+296%0.9% | 0.9−47.2%0.4% | 1.7−39.2%1.0% | 2.7−17.2%1.8% | 3.3+314%1.8% | 0.8+1269%0.5% | 0.1—0.0% | |
| Income before tax | −65—−56.2% | −16−128%−8.6% | 56—13.9% | −16r−16—−4.0% | −9.3—−4.0% | −3.5−117%−2.1% | 21−32.7%13.8% | 32−22.7%17.5% | 41+102%24.6% | 20—15.9% | |
| Income tax | 1.8+0.1%1.6% | 1.8−30.9%1.0% | 2.6+78.5%0.6% | 1.5−89.4%0.4% | 14+20.2%5.9% | 11+144%6.6% | 4.7−58.7%3.0% | 11+12.3%6.2% | 10+1572%6.0% | 0.6—0.5% | |
| Net income including minority interests | — | −20−136%−10.5% | 54—13.2% | −17r−18—−4.4% | −23—−9.8% | −15−190%−8.7% | 17−18.3%10.8% | 20−34.1%11.2% | 31+56.9%18.5% | 20—15.4% | |
| Net income attributable to shareholders | −69—−59.8% | −20−136%−10.5% | 54—13.2% | −17r−18—−4.4% | −23—−9.8% | −15−190%−8.7% | 17−18.3%10.8% | 20−34.1%11.2% | 31+56.9%18.5% | 20—15.4% | |
| Earnings per share, basic | -0.94—— | -0.26−136%— | 0.73—— | -0.24r-0.25—— | -0.32−245%— | 0.22r-0.22−18.5%— | 0.27−18.2%— | 0.33−36.5%— | 0.52+48.6%— | 0.35—— | |
| Earnings per share, diluted | -0.94—— | -0.26−136%— | 0.72—— | -0.24r-0.25—— | -0.32−245%— | 0.22r-0.22−18.5%— | 0.27−18.2%— | 0.33−35.3%— | 0.51+45.7%— | 0.35—— | |
| Shares, weighted average (basic) | 73−1.3%— | 74+1.5%— | 73+1.2%— | 73+0.7%— | 72+6.6%— | 68+9.5%— | 62+0.9%— | 61+3.5%— | 59+6.2%— | 56—— | |
| Shares, weighted average (diluted) | 73−1.3%— | 74+0.1%— | 74+2.6%— | 73+0.7%— | 72+6.6%— | 68+8.6%— | 62−0.6%— | 63+2.5%— | 61+8.0%— | 57—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 199−25.6%49.4% | 268−7.8%55.8% | 290+246%60.1% | 84−28.1%18.9% | 117−27.4%25.3% | 161+112%35.4% | 76−14.4%21.7% | 88+24.5%28.0% | 71−34.2%24.0% | 108—51.9% | |
| Short-term investments | — | — | 0−100%0.0% | 27−25.9%6.0% | 36−25.4%7.9% | 49−39.7%10.7% | 81+18.3%23.1% | 68−17.9%21.6% | 83+644%28.0% | 11—5.4% | |
| Receivables | 22−6.8%5.5% | 24−40.7%5.0% | 40−43.3%8.3% | 71+56.2%15.9% | 45+16.7%9.8% | 39+5.1%8.5% | 37+6.0%10.6% | 35−18.1%11.0% | 43+114%14.4% | 20—9.5% | |
| Inventory | 31−9.2%7.7% | 34−28.2%7.1% | 48−50.2%9.9% | 96r96+80.1%21.5% | 53+66.8%11.5% | 32+37.6%7.0% | 23+1.2%6.6% | 23+18.3%7.3% | 19+63.9%6.5% | 12—5.7% | |
| Other current assets | 2.4r4.1−30.8%0.6% | 3.5+56.7%0.7% | 2.2−94.6%0.5% | 42+4.3%9.4% | 40r29+708%8.6% | 4.9−13.1%1.1% | 5.7+84.0%1.6% | 3.1+24.1%1.0% | 2.5+16.0%0.8% | 2.1—1.0% | |
| Current assets | 262−21.4%65.0% | 333−13.8%69.5% | 386+18.8%80.0% | 325r326+8.6%73.2% | 299r288+3.6%64.9% | 289+28.7%63.6% | 225+2.4%64.3% | 219−1.2%69.5% | 222+41.8%74.9% | 156—75.2% | |
| Property, plant and equipment | 39−13.1%9.7% | 45−0.7%9.4% | 45−23.6%9.4% | 59−19.1%13.4% | 73r88+41.6%15.9% | 52+70.9%11.4% | 30+24.9%8.7% | 24+13.7%7.7% | 21+6.7%7.2% | 20—9.6% | |
| Right-of-use (leased) assets | 12−10.8%3.0% | 13+9.6%2.8% | 12+18.0%2.5% | 10+14.8%2.3% | 9.1+103%2.0% | 4.5−10.7%1.0% | 5.0—1.4% | — | — | — | |
| Goodwill | 43+7.5%10.8% | 40+13.0%8.4% | 36+1.7%7.4% | 35−12.8%7.9% | 40−0.2%8.7% | 40+11.5%8.9% | 36+95.5%10.4% | 19−7.8%5.9% | 20+6.9%6.8% | 19—9.0% | |
| Other intangible assets | 19+9.2%4.7% | 17+1346%3.6% | 1.2−89.7%0.2% | 12−18.5%2.6% | 14−19.9%3.1% | 18+22.0%3.9% | 15+186%4.2% | 5.1−37.5%1.6% | 8.2−20.5%2.8% | 10—5.0% | |
| Long-term investments | — | — | — | 0−100%0.0% | 17−64.4%3.7% | 48+42.8%10.5% | 33−25.3%9.6% | 45+116%14.2% | 21—7.0% | — | |
| Non-current assets | 141−3.5%35.0% | 146+51.9%30.5% | 96−19.0%20.0% | 119−26.4%26.8% | 162r173−2.4%35.1% | 166+32.7%36.4% | 125+29.6%35.7% | 96—30.5% | — | — | |
| Total assets | 403−15.9%100% | 480−0.7%100% | 483+8.7%100% | 444r445−3.6%100% | 461+1.4%100% | 454+30.1%100% | 349+10.7%100% | 316+6.5%100% | 296+42.4%100% | 208—100% | |
| Accounts payable | 6.5−20.2%1.6% | 8.2−37.9%1.7% | 13−65.4%2.7% | 38r39+35.7%8.6% | 28+61.0%6.1% | 17+81.9%3.8% | 9.6−9.7%2.7% | 11+3.6%3.4% | 10+121%3.5% | 4.6—2.2% | |
| Current liabilities | 40+18.9%9.9% | 33−15.3%7.0% | 40−42.8%8.2% | 69r70+1.5%15.5% | 68+46.4%14.8% | 46+42.1%10.2% | 33+16.9%9.4% | 28−13.2%8.9% | 32+86.0%10.9% | 17—8.3% | |
| Lease liabilities (non-current) | 11−11.8%2.7% | 12+10.4%2.6% | 11+22.6%2.3% | 9.1+26.4%2.0% | 7.2+101%1.6% | 3.6−14.6%0.8% | 4.2—1.2% | — | — | — | |
| Non-current liabilities | 23−37.1%5.6% | 36+184%7.5% | 13+18.2%2.6% | 11−13.7%2.4% | 12+31.7%2.7% | 9.4−0.3%2.1% | 9.4+124%2.7% | 4.2—1.3% | — | — | |
| Total liabilities | 62−10.1%15.5% | 69+32.9%14.5% | 52−34.6%10.8% | 80r81−0.9%18.0% | 80+43.9%17.5% | 56+32.6%12.3% | 42+30.9%12.1% | 32—10.2% | — | — | |
| Retained earnings | −172—−42.7% | −103—−21.6% | −84—−17.4% | −138r−138—−31.0% | −120—−26.1% | −97—−21.4% | −83—−23.6% | −99—−31.4% | −120—−40.3% | −150—−72.4% | |
| Shareholders' equity | 341−16.9%84.5% | 410−4.7%85.5% | 431+18.2%89.2% | 364r364−4.2%82.0% | 381−4.5%82.5% | 399+29.8%87.7% | 307+8.4%87.9% | 283+9.8%89.8% | 258+38.9%87.1% | 186—89.4% | |
| Total liabilities and equity | 403−15.9%100% | 480−0.7%100% | 483+8.7%100% | 444r445−3.6%100% | 461+1.4%100% | 454+30.1%100% | 349+10.7%100% | 316+6.5%100% | 296+42.4%100% | 208—100% | |
| Shares outstanding | 70−5.6%— | 75+1.5%— | 74+1.1%— | 73+0.9%— | 72+0.5%— | 72+16.2%— | 62+0.7%— | 61+1.0%— | 61+8.3%— | 56—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 10−6.3%8.9% | 11−48.1%5.9% | 21+36.8%5.2% | 15+31.3%4.0% | 12+24.2%5.0% | 9.4+27.9%5.5% | 7.3+13.8%4.7% | 6.5+6.2%3.5% | 6.1r6.4+6.8%3.6% | 5.7r5.7—4.4% | |
| Share-based compensation | 10−14.9%8.8% | 12+11.1%6.4% | 11−7.7%2.6% | 12+48.9%3.0% | 7.8+9.4%3.3% | 7.1+76.0%4.2% | 4.1−73.4%2.6% | 15+119%8.4% | 7.0+15.0%4.2% | 6.1—4.7% | |
| Cash from operating activities | −49−279%−42.6% | 27−80.7%14.7% | 142—34.9% | −47—−12.2% | −35−709%−15.1% | 5.8−40.8%3.4% | 9.8−74.9%6.3% | 39+38.8%21.5% | 28+14.5%16.9% | 25r23—19.2% | |
| Capital expenditure | −4.2—−3.6% | −3.8—−2.0% | −5.8—−1.4% | −6.8—−1.7% | −22r−37—−9.4% | −27—−15.5% | −9.3—−6.0% | −6.3—−3.5% | −4.3—−2.6% | −4.4—−3.4% | |
| Acquisitions, net of cash acquired | −3.6—−3.1% | −5.0—−2.7% | 0—0.0% | 0—0.0% | — | −3.0—−1.8% | −24—−15.4% | — | — | — | |
| Cash from investing activities | −6.8—−5.9% | −39−159%−21.0% | 66+214%16.3% | 21—5.4% | −5.5—−2.4% | −14—−8.2% | −20—−12.8% | −17—−9.6% | −96—−57.7% | −8.1—−6.3% | |
| Debt repaid | — | — | — | — | — | — | −0.7—−0.5% | — | — | — | |
| Shares issued | — | — | — | — | — | 95—55.3% | — | — | — | — | |
| Shares bought back | −15—−13.1% | 0r−3.5—0.0% | 0r−1.9—0.0% | −2.3—−0.6% | −2.1—−0.9% | −2.1—−1.2% | −3.7—−2.4% | −3.6—−2.0% | −1.2—−0.7% | −3.4—−2.7% | |
| Cash from financing activities | −17—−14.7% | −4.2—−2.2% | −3.0—−0.7% | −3.8—−1.0% | −2.8−103%−1.2% | 92—53.9% | −4.7—−3.0% | −1.9−106%−1.0% | 30—18.2% | −1.2—−0.9% | |
| Exchange-rate effect on cash | — | — | — | — | — | — | — | — | 0.8+164%0.5% | 0.3—0.2% | |
| Change in cash | −68—−59.5% | −23−111%−12.2% | 206—50.9% | −33—−8.5% | −44−152%−18.8% | 85—49.5% | −13−182%−8.2% | 16—8.6% | −37−335%−22.1% | 16r14—12.2% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 116−7.5%100% | 31+14.1%100% | 31−1.9%100% | 28−6.7%100% | 27*−28.5%100% | 27−32.1%100% | 31−42.5%100% | 30−44.7%100% | 37*−50.7%100% | 40—100% | 54—100% | 54—100% | 76*—100% | |
| Cost of revenue | 66−11.7%56.9% | 17+10.6%54.8% | 17−4.2%56.5% | 16−8.6%57.7% | 16*−33.9%59.0% | 15−33.0%56.5% | 18−39.0%57.9% | 18−41.4%58.9% | 24*−41.4%63.8% | 23—57.2% | 30—54.6% | 30—55.5% | 41*—53.7% | |
| Gross profit | 50−1.5%43.1% | 14+18.7%45.2% | 13+1.2%43.5% | 12−4.0%42.3% | 11*−19.2%41.0% | 12−31.0%43.5% | 13−46.7%42.1% | 12−48.9%41.1% | 14*−61.4%36.2% | 17—42.8% | 25—45.4% | 24—44.5% | 35*—46.3% | |
| Research and development | 42+13.3%36.3% | 7.6−24.5%24.7% | 9.4−17.2%30.8% | 14+42.2%48.9% | 11*+87.6%42.7% | 10+79.7%37.3% | 11+72.8%36.5% | 9.6+24.1%32.1% | 6.1*−12.9%16.3% | 5.6—14.1% | 6.6—12.1% | 7.7—14.3% | 7.0*—9.2% | |
| Selling and marketing | 27−0.0%22.8% | 6.6+4.1%21.2% | 6.6+3.6%21.6% | 6.8−1.3%24.2% | 6.6*−5.8%24.6% | 6.3−17.3%23.3% | 6.4−19.6%20.4% | 6.9−18.8%22.9% | 7.0*+1.2%18.7% | 7.6—19.1% | 7.9—14.6% | 8.4—15.6% | 6.9*—9.1% | |
| General and administrative | 51+0.1%43.7% | 12+8.2%38.8% | 14+13.8%47.1% | 15+3.2%52.1% | 9.8*−23.9%36.7% | 11+12.7%40.9% | 13+7.0%40.6% | 14+21.2%47.1% | 13*−7.9%34.5% | 9.8—24.6% | 12—21.8% | 12—21.5% | 14*—18.5% | |
| Operating expenses | 101−12.3%86.8% | 27−3.4%87.1% | 7.9−74.7%25.7% | 35+16.7%126% | 31*+19.6%116% | 28+20.8%103% | 31+13.7%99.8% | 30−3.6%100% | 26*−16.8%69.4% | 23—57.8% | 27—50.5% | 31—57.6% | 31*—41.2% | |
| Operating income | −51—−43.8% | −13—−41.9% | 5.4—17.8% | −23—−83.3% | −20*—−75.1% | −16—−59.4% | −18—−57.7% | −18—−59.3% | −12*−419%−33.2% | −6.0—−15.0% | −2.7—−5.0% | −7.1—−13.1% | 3.9*—5.1% | |
| Interest and finance income | — | — | 1.2−41.9%3.9% | 1.2−43.4%4.4% | 1.8*−28.9%6.7% | 2.1−28.9%7.6% | 2.1−31.6%6.6% | 2.2−28.7%7.2% | 2.5*—6.8% | 2.9—7.2% | 3.0—5.6% | 3.0—5.6% | — | |
| Share of profit of associates | −2.8—−2.4% | −0.6—−1.9% | −0.5—−1.7% | −1.1—−3.9% | −0.6*—−2.4% | −0.4—−1.4% | −0.8—−2.6% | −0.5—−1.8% | −0.5*—−1.4% | −0.6—−1.5% | −0.6—−1.0% | 0—0.0% | 0*—0.0% | |
| Other non-operating income (expense) | — | — | 0.2—0.8% | 0.2—0.6% | 0.1*—0.3% | 0.2+62.1%0.6% | 0—0.0% | −0.0−108%−0.1% | −0.7r−9.7*−106%−1.9% | 0.1r2.8—0.2% | −0.0r3.1—−0.1% | 0.3r3.5—0.5% | 11r17*—14.6% | |
| Income before tax | −45—−38.8% | −12—−38.1% | 6.8—22.2% | −22—−77.8% | −18*—−68.9% | −13—−49.1% | −17−5281%−54.1% | −16—−53.4% | −9.5*−146%−25.4% | −3.2—−8.1% | 0.3—0.6% | −3.6—−6.7% | 21*—27.3% | |
| Income tax | 0.5−77.0%0.5% | 0.7+1406%2.3% | 0.1−97.3%0.2% | −0.4—−1.5% | 0.2*−72.3%0.8% | 0.0−93.1%0.2% | 2.0+425%6.4% | −0.5—−1.5% | 0.8*+17.2%2.0% | 0.7—1.7% | 0.4—0.7% | −0.0—−0.0% | 0.6*—0.9% | |
| Net income attributable to shareholders | −49—−41.7% | −13—−42.4% | 6.2—20.4% | −22—−80.1% | −19*—−72.1% | −14—−50.6% | −20—−63.0% | −16—−53.6% | −11*−154%−28.8% | −4.5—−11.3% | −0.6—−1.1% | −3.6—−6.6% | 20*—26.5% | |
| Earnings per share, basic | — | -0.19—— | 0.09—— | -0.32—— | — | -0.19—— | -0.26—— | -0.21—— | — | -0.06—— | -0.01—— | -0.05—— | — | |
| Earnings per share, diluted | — | -0.19—— | 0.09—— | -0.32—— | — | -0.19—— | -0.26—— | -0.21—— | — | -0.06—— | -0.01—— | -0.05—— | — | |
| Shares, weighted average (basic) | 69−5.5%— | 69−5.5%— | 69−7.4%— | 70−6.9%— | — | 73−2.1%— | 75+0.5%— | 75+1.2%— | — | 75—— | 74—— | 74—— | — | |
| Shares, weighted average (diluted) | 69−5.5%— | 69−5.5%— | 70−5.9%— | 70−6.9%— | — | 73−2.1%— | 75+0.5%— | 75+1.2%— | — | 75—— | 74—— | 74—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 148—42.4% | 148−31.5%42.4% | 161−31.5%44.5% | 177−28.5%46.7% | 199−25.6%49.4% | 216−22.3%51.2% | 235−9.2%52.7% | 248+0.2%54.1% | 268−7.8%55.8% | 279—60.0% | 258—55.4% | 247—52.9% | 290—60.1% | |
| Short-term investments | — | — | — | — | — | — | — | — | — | — | 9.1—2.0% | 17—3.6% | 0—0.0% | |
| Receivables | 30—8.7% | 30+25.2%8.7% | 26−1.2%7.1% | 25+15.3%6.5% | 22−6.8%5.5% | 24−9.8%5.7% | 26−32.0%5.8% | 22−36.8%4.7% | 24−40.7%5.0% | 27—5.8% | 38—8.2% | 34—7.3% | 40—8.3% | |
| Inventory | 30—8.7% | 30−8.9%8.7% | 30−9.9%8.3% | 30−15.1%8.0% | 31−9.2%7.7% | 33−14.1%7.9% | 33−12.8%7.5% | 36−17.4%7.8% | 34−28.2%7.1% | 39—8.4% | 38—8.2% | 43—9.2% | 48—9.9% | |
| Other current assets | 1.8—0.5% | 1.8−56.3%0.5% | 1.6−63.4%0.4% | 1.9−40.3%0.5% | 2.4r4.1−30.8%0.6% | 4.1+51.7%1.0% | 4.2+12.6%1.0% | 3.1+10.8%0.7% | 3.5+56.7%0.7% | 2.7—0.6% | 3.8—0.8% | 2.8—0.6% | 2.2—0.5% | |
| Current assets | 215—61.6% | 215−23.9%61.6% | 223−26.0%61.8% | 241−23.3%63.5% | 262−21.4%65.0% | 283−19.2%66.9% | 301−14.1%67.7% | 314−10.0%68.6% | 333−13.8%69.5% | 350—75.4% | 351—75.3% | 349—74.5% | 386—80.0% | |
| Property, plant and equipment | 37—10.4% | 37−10.5%10.4% | 39−8.5%10.7% | 38−12.3%10.0% | 39−13.1%9.7% | 41+7.0%9.6% | 42+4.6%9.5% | 43+1.3%9.4% | 45−0.7%9.4% | 38—8.2% | 40—8.6% | 43—9.1% | 45—9.4% | |
| Right-of-use (leased) assets | 11—3.1% | 11−12.1%3.1% | 11−12.7%3.1% | 12−11.2%3.0% | 12−10.8%3.0% | 12+23.6%2.9% | 13+24.0%2.9% | 13+23.0%2.8% | 13+9.6%2.8% | 9.9—2.1% | 10—2.2% | 11—2.3% | 12—2.5% | |
| Goodwill | 43—12.2% | 43+3.5%12.2% | 43+2.3%11.8% | 43+6.4%11.4% | 43+7.5%10.8% | 41+17.1%9.8% | 42+19.4%9.4% | 40+15.0%8.8% | 40+13.0%8.4% | 35—7.6% | 35—7.5% | 35—7.5% | 36—7.4% | |
| Other intangible assets | 19—5.4% | 19+9.0%5.4% | 19+9.1%5.2% | 19+9.4%5.0% | 19+9.2%4.7% | 17+2487%4.1% | 17+1983%3.9% | 17+1614%3.8% | 17+1346%3.6% | 0.7—0.1% | 0.8—0.2% | 1.0—0.2% | 1.2—0.2% | |
| Non-current assets | 134—38.4% | 134−4.2%38.4% | 138−4.2%38.2% | 138−3.8%36.5% | 141−3.5%35.0% | 140+23.0%33.1% | 144+24.6%32.3% | 144+20.8%31.4% | 146+51.9%30.5% | 114—24.6% | 115—24.7% | 119—25.5% | 96—20.0% | |
| Total assets | 349—100% | 349−17.4%100% | 361−19.0%100% | 379−17.1%100% | 403−15.9%100% | 423−8.8%100% | 445−4.6%100% | 458−2.1%100% | 480−0.7%100% | 464—100% | 466—100% | 468—100% | 483—100% | |
| Accounts payable | 7.8—2.2% | 7.8+22.2%2.2% | 8.4+31.7%2.3% | 11+35.9%2.8% | 6.5−20.2%1.6% | 6.4−33.6%1.5% | 6.4−29.8%1.4% | 7.8−38.3%1.7% | 8.2−37.9%1.7% | 9.6—2.1% | 9.1—1.9% | 13—2.7% | 13—2.7% | |
| Current liabilities | 25—7.2% | 25−37.6%7.2% | 25−40.7%7.0% | 44+73.4%11.6% | 40+18.9%9.9% | 40+44.9%9.5% | 42+46.8%9.5% | 25−12.7%5.6% | 33−15.3%7.0% | 28—6.0% | 29—6.2% | 29—6.2% | 40—8.2% | |
| Lease liabilities (non-current) | 9.4—2.7% | 9.4−16.0%2.7% | 9.8−17.1%2.7% | 10−13.9%2.7% | 11−11.8%2.7% | 11+19.4%2.7% | 12+15.7%2.7% | 12+12.1%2.6% | 12+10.4%2.6% | 9.4—2.0% | 10—2.2% | 11—2.3% | 11—2.3% | |
| Non-current liabilities | 17—4.9% | 17−17.4%4.9% | 18−19.6%4.9% | 22−39.4%5.7% | 23−37.1%5.6% | 21+94.4%4.9% | 22+88.5%4.9% | 36+194%7.8% | 36+184%7.5% | 11—2.3% | 12—2.5% | 12—2.6% | 13—2.6% | |
| Total liabilities | 42—12.1% | 42−30.7%12.1% | 43−33.5%11.9% | 66+7.4%17.4% | 62−10.1%15.5% | 61+58.7%14.4% | 64+58.8%14.5% | 61+48.5%13.4% | 69+32.9%14.5% | 39—8.3% | 41—8.7% | 41—8.8% | 52—10.8% | |
| Retained earnings | −201—−57.6% | −201—−57.6% | −188—−52.2% | −195—−51.3% | −172—−42.7% | −153—−36.1% | −139—−31.3% | −119—−26.1% | −103—−21.6% | −93—−20.0% | −88—−18.9% | −88—−18.7% | −84—−17.4% | |
| Shareholders' equity | 307—87.9% | 307−15.2%87.9% | 318−16.5%88.1% | 313−20.9%82.6% | 341−16.9%84.5% | 362−14.9%85.6% | 381−10.6%85.5% | 396−7.0%86.6% | 410−4.7%85.5% | 426—91.7% | 426—91.3% | 426—91.2% | 431—89.2% | |
| Total liabilities and equity | 349—100% | 349−17.4%100% | 361−19.0%100% | 379−17.1%100% | 403−15.9%100% | 423−8.8%100% | 445−4.6%100% | 458−2.1%100% | 480−0.7%100% | 464—100% | 466—100% | 468—100% | 483—100% | |
| Shares outstanding | 69—— | 69−4.5%— | 69−6.5%— | 69−7.6%— | 70−5.6%— | 72−3.1%— | 74−1.1%— | 75+1.6%— | 75+1.5%— | 75—— | 75—— | 74—— | 74—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 9.3−9.4%8.0% | 2.2−10.4%7.1% | 2.4−6.1%7.7% | 2.3−16.6%8.4% | 2.4*−3.6%9.0% | 2.5−19.5%9.1% | 2.5−3.1%8.1% | 2.8+3.0%9.4% | 2.5*−30.1%6.7% | 3.0—7.6% | 2.6—4.8% | 2.7—5.0% | 3.6*—4.7% | |
| Share-based compensation | 8.8−23.1%7.6% | 2.3−19.6%7.4% | 2.3−27.7%7.5% | 2.8+3.0%9.9% | 1.5*−46.8%5.5% | 2.8−1.8%10.5% | 3.2−4.7%10.1% | 2.7−9.5%9.0% | 2.7*−12.3%7.3% | 2.9—7.2% | 3.3—6.1% | 3.0—5.5% | 3.1*—4.1% | |
| Cash from operating activities | −44—−37.6% | −11*—−35.2% | −9.9*—−32.4% | −14—−49.8% | −9.0*−8353%−33.6% | −10*−179%−37.2% | −10*−230%−32.7% | −20−393%−65.9% | 0.1*−99.7%0.3% | 13*—31.8% | 7.8r7.8*—14.4% | 6.7r6.7—12.4% | 41*—54.5% | |
| Capital expenditure | −5.9—−5.1% | −1.7*—−5.4% | −2.4*—−7.9% | −0.9—−3.3% | −0.9*—−3.4% | −0.9*—−3.4% | −1.9*—−6.2% | −0.4—−1.4% | −0.5*—−1.2% | −0.1*—−0.4% | −1.6*—−3.0% | −1.6—−2.9% | −1.3*—−1.7% | |
| Cash from investing activities | −9.4—−8.1% | −1.7*—−5.4% | −2.4*—−7.9% | −0.9−347%−3.3% | −4.4*—−16.5% | −0.8*−111%−3.0% | −1.9*−134%−6.2% | 0.4—1.2% | −5.5*−118%−14.7% | 7.3*—18.4% | 5.7*—10.4% | −47—−86.0% | 31*—40.3% | |
| Shares bought back | −12—−10.4% | 0*—0.0% | −2.0*—−6.5% | −5.0—−17.9% | −5.0*—−18.8% | −5.0*—−18.5% | −5.0r−4.1*—−16.0% | 0r−0.9—0.0% | 0r−0.0*—0.0% | 0r−0.1*—0.0% | — | −1.5—−2.7% | — | |
| Cash from financing activities | −14—−11.8% | −0.0*—−0.1% | −2.2*—−7.3% | −6.3—−22.5% | −5.1*—−19.1% | −5.1*—−18.8% | −5.8*—−18.6% | −1.0—−3.2% | −0.1*—−0.3% | −0.7r−0.7*—−1.8% | −2.0r−2.0*—−3.8% | −1.3r−1.3—−2.4% | −0.4*—−0.5% | |
| Change in cash | −68—−58.7% | −12*—−39.9% | −16*—−53.5% | −22—−79.9% | −17*—−64.3% | −18*−189%−66.8% | −13*−217%−41.6% | −20—−67.5% | −11*−115%−28.9% | 20*—50.9% | 11*—20.4% | −43—−79.9% | 73*—96.0% | |
| Report | Worked out | 10-Q/A | 10-Q | 10-Q | 10-Q/A | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What OraSure Technologies, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Products and services$109 M95%-41%
- Other$6 M5.2%+389%
Countries and regions
- 🇺🇸 USA$78 M68%-44%
- Africa$24 M21%-27%
- Europe$7 M6.4%-12%
- Other regions$5 M4.7%-2.2%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at OraSure Technologies, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Ms. Eglinton Manner | $4.3 M | $671 K | $1.6 M | $23 (peers $81) |
| 2024Ms. Eglinton Manner | $5.6 M | −$5.7 M | $1.5 M | $45 (peers $85) |
| 2023Ms. Eglinton Manner | $6.7 M | $13.8 M | $1.6 M | $102 (peers $106) |
| 2022Manner Carrie Eglinton | $6.7 M | $6.6 M | $1.5 M | $60 (peers $99) |
| 2021Dr. Tang | $3.0 M | $2.7 M | $1.1 M | $108 (peers $125) |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at OraSure Technologies, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Acquisition or sale completed 1 · Directors and officers 8 · Material agreement 2 · Bylaws or fiscal year changed 2 · Shareholder vote 3 · Results announced 10
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersBylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officersMaterial agreement | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Acquisition or sale completedMaterial agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officersBylaws or fiscal year changedShareholder vote | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026
Acquisitions and funding#
2 acquisitions, $32 M paid where reported
Businesses it acquired
| Acquired | Acquisition date | Completion | Price | Stake | Source |
|---|---|---|---|---|---|
| BioMedomics, Inc | 2025 | — | $4 M | — | Annual report |
| Sherlock Biosciences | 2024 | — | $28 M | — | Annual report |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by OraSure Technologies, Inc.#
$40 K spent on lobbying the US Congress and federal agencies in 2025, most often on budget/appropriations and health issues.
- Budget/Appropriations4 reports
- Health Issues4 reports
Lobbying firms hired in 2025
Health and Medicine Counsel $40 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $30 K | — | 3 |
| 2025 | $40 K | — | 4 |
| 2024 | $40 K | — | 4 |
| 2023 | $40 K | — | 4 |
| 2022 | $40 K | — | 4 |
| 2021 | $40 K | — | 4 |
| 2020 | $40 K | — | 4 |
| 2019 | $40 K | — | 4 |
| 2018 | $40 K | — | 4 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “ORASURE TECHNOLOGIES, INC.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
H-1B hiring at OraSure Technologies, Inc.#
3 labor condition applications certified in fiscal 2026 for 3 positions, at a median wage of $99 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Manufacturing Engineer IIManufacturing Engineers | 2 | $99 K |
| Senior ScientistBiological Scientists, All Other | 1 | $91 K |
Where: Bethlehem, PA 2 · Morrisville, NC 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 3 | 3 | $99 K | 3 |
| FY2024 | 3 | 3 | $85 K | 3 |
| FY2021 | 2 | 2 | $85 K | 2 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as ORASURE TECHNOLOGIES, INC.
Product recalls by OraSure Technologies, Inc.#
7 recalls since 2015, 26,582 units in the notices that give a number. Medical devices (FDA): 7.
| Date | What and why | Units | Notice |
|---|---|---|---|
| Methamphetamine Intercept Microplate kit EIA - IVD qualitative determination of methamphetamine in oral fluid, PN 11041C.Incorrect lot of Substrate Reagent (TMB) may be included in the kit. The original kit box labeling and the specification sheet listed the Substrate Reagent (TMB) lot 6676239, but contained Substrate Reagent (TMB) lot 6679623, should not affect performance.Medical devicesClass III | 16 | Z-1183-2021 | |
| Pointts sistema de ellmlnact!;o de verrugas OTC - Brazil Catalog Number: 1001-0280 - Product Usage: indicated for over-the-counter a cryosurgical system for the treatment of skin tags. (and 2 more products)Unit boxes not properly sealedMedical devicesClass III | 23,220 | Z-3003-2020 | |
| Orasure Technologies Interept Benzodiazopene Miro-Plate EIA-Benzo EIA 2 plate Matrix Oral Fluid Coated Micro-Plate. IVD Immunoassay for Benzodiazepines, Product Number: 1110IT (and 1 more products)Incorrect lot number for Standard Oral Fluid Negative Calibrator on specification sheet included in kit and/or additionally same error on unit boxMedical devicesClass III | 13 | Z-2877-2020 | |
| Cocaine Metabolite MICRO-PLATE EIA, Catalog Number: 1122SC, UDI: (0100608337000429(17)180228(10)000The controls and calibrators contained within the cocaine test kit may cause false positive results with the negative control.Medical devicesClass III | 10 | Z-1419-2018 | |
| Barbiturates Intercept Micro-Plate EIA (enzyme immunoassay, barbiturate) Product is intended for use by clinical laboratories in the qualitative determination of barbiturates in oral fluids.Shipping error. Cocaine metabolite Microplate distributed instead of Barbiturate Microplate due to incorrect selection of Microplate during manufacturing.Medical devicesClass III | 4 | Z-0722-2017 | |
| OraQuick Ebola Rapid Antigen Test, Product Code 3001-2807; Intended for the qualitative detection of antigens for Ebola viruses.Failed stability testing at 8 months. This lot produced intermittent false negative results for the positive kit control with devices stored at 30C conditions.Medical devicesClass I | 3,075 | Z-2403-2016 | |
| OraQuick HCV Visual Reference Panel Intended to assist new operation in becoming proficient at reading specimens with antibody levels near the limit of detection of the device.OraSure Technologies, Inc. discovered the package insert included with the OraQuick HCV Rapid Antibody test Visual Reference Panel may be incorrect due to a complaint received from one of their customers. The customer reported they received the Ora Quick Ebola Visual Reference Panel instead of an OraQuick HCV Visual Reference Panel.Medical devicesClass III | 244 | Z-1509-2016 |
Source: NHTSA, CPSC and FDA recall notices. Recalls filed under a subsidiary with a different name may be missing. The number of recalls says nothing about their seriousness
How OraSure Technologies, Inc. compares in Medical Instruments
- Market cap$262 M · higher than 29% of 116
- Revenue$115 M · higher than 21% of 120
- Net margin-41.7% · higher than 7% of 114
- Revenue growth-38.1% · higher than 2% of 49
- Price / sales2.3× · lower than 65% of 85
- Price / book0.8× · lower than 95% of 84
- FCF yield-20.3% · higher than 8% of 39
- 🇺🇸 InfuSystems Holdings$255 M
- 🇰🇷 Dentium Co., Ltd$252 M
- 🇮🇩 PT Mark Dynamics Indonesia Tbk$229 M
- 🇹🇼 Bioteque Corporation$221 M
- 🇺🇸 Pro-Dex, Inc.$199 M
- 🇹🇼 Medeon Biodesign, Inc.$192 M
Peer comparison · Medical Instruments
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| OraSure Technologies, Inc.🇺🇸 | $262 M | — | -41.7% | -38.1% |
| Intuitive Surgical, Inc.🇺🇸 | $155.6 B | 52.6× | 25.5% | +20.5% |
| EssilorLuxottica S.A.🇫🇷 | $88.0 B | 32.1× | 8.1% | +4.5% |
| HOYA Corporation🇯🇵 | $56.2 B | 32.8× | 25.4% | — |
| Becton, Dickinson and Company🇺🇸 | $54.0 B | 57.4× | 4.2% | +8.2% |
| Alcon Inc.🇨🇭 | $37.1 B | 37.9× | 9.4% | +4.9% |
| ResMed Inc.🇺🇸 | $35.3 B | 22.1× | 27.8% | +9.8% |
| West Pharmaceutical Services, Inc.🇺🇸 | $27.1 B | 42.4× | 18.8% | +6.3% |
| Terumo Corporation🇯🇵 | $24.9 B | 27.0× | 12.0% | — |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- InfuSystems Holdings$255 M
- Dentium Co., Ltd$252 M
- PT Mark Dynamics Indonesia Tbk$229 M
- Bioteque Corporation$221 M
- Pro-Dex, Inc.$199 M
- Medeon Biodesign, Inc.$192 M
Sources and freshness
- Market cap:
- Oct 23, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on 2021
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, Wikipedia, Wikidata, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at OraSure Technologies, Inc.? Verify and update this profile — free
Show OraSure Technologies, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.